SCREENERS

GAD-7

Generalized Anxiety Disorder Scale

The GAD‑7 (Generalized Anxiety Disorder‑7) is a validated, self‑reported questionnaire used to screen for generalized anxiety disorder and quantify the severity of anxiety symptoms in adults. It asks patients to rate how often they have experienced key anxiety symptoms over the prior two weeks, producing a 0–21 severity score that supports evidence‑based clinical decision‑making in primary care and behavioral health settings.

Delivered digitally through the BrainCheck platform, the GAD‑7 can typically be completed in approximately five minutes, either in‑clinic or remotely, helping clinicians efficiently identify patients who may benefit from further anxiety evaluation, monitoring, or treatment.

 

Benefits include:

  • Assess the severity of generalized anxiety symptoms on a validated 0–21 scale.

  • 5‑minute digital screener that can be completed in‑clinic or via remote / telehealth.

  • Patient self‑administration reduces clinician burden and saves time for both patients and care teams.

  • Structured scoring and tracking support ongoing symptom monitoring and treatment planning.

What the GAD-7 Measures

Core symptoms of generalized anxiety disorder include excessive worry and difficulty controlling worry.

Symptom frequency over the prior two weeks was captured on a standardized response scale.

Overall anxiety severity categories (minimal, mild, moderate, severe), based on the total score from 0 to 21.

Common Clinical Use Cases

  • Routine anxiety screening in primary care and family medicine.
  • Behavioral health, psychology, and psychiatry workflows in which anxiety symptoms are evaluated or monitored.
  • Tracking response to interventions over time, including psychotherapy, medication, and lifestyle changes.
  • Supporting referrals, shared decision‑making, and documentation of anxiety symptom burden in the medical record.

On the BrainCheck Platform

  • Fully digital, patient self‑administered screener that can be used on tablets or computers.
  • Automated scoring with longitudinal tracking of GAD‑7 scores across visits.
  • Designed to integrate into broader cognitive and behavioral health assessments within BrainCheck.
  • Supports coordinated brain health care by combining anxiety screening with other cognitive screeners and assessments.

Frequently Asked Questions

Key things to know about the GAD-7

What is the GAD‑7 used for?

The GAD‑7 is a validated self‑report questionnaire used to screen for generalized anxiety disorder and measure the severity of anxiety symptoms in adults over the prior two weeks. It helps clinicians quickly identify patients who may be experiencing clinically significant anxiety.

Is the GAD‑7 a diagnostic test for anxiety?

No. The GAD‑7 is a screening tool, not a stand‑alone diagnostic instrument. Results are intended to support clinical judgement and help guide follow‑up evaluation, diagnosis, ongoing monitoring, or treatment planning in the context of a full clinical assessment.

How is the GAD‑7 scored and interpreted?

Each of the seven items is scored from 0 to 3 based on symptom frequency, generating a total score from 0 to 21. Higher scores indicate greater anxiety symptom burden. Clinicians use established severity cut‑offs to categorize anxiety and track changes over time in response to treatment or changes in clinical status.

More Clinical Evaluation Tools

BrainCheck offers a broad library of clinical evaluation tools designed to support early identification, risk stratification, and longitudinal monitoring of cognitive health across clinical and research settings.

See More